← Back to front page
Asia · Regional markets · Pulse (Maeil Business)

Onconic Therapeutics posts 70% sales growth despite tripling R&D spending

Published by Pulse (Maeil Business) · South Korea 15 h ago
Onconic Therapeutics CI
Onconic Therapeutics CI · Pulse (Maeil Business)

Detailed summary

The company said Monday that revenue rose 70.3 percent from a year earlier to 64.4 billion won ($48.2 million) in the January-September period, while operating profit reached 3…

South Korean drug developer Onconic Therapeutics remained profitable in the first nine months of 2026 despite more than tripling its research and development spending, supported by growing domestic prescriptions of its acid reflux treatment Jaqbo (zastaprazan citrate).

The company said Monday that revenue rose 70.3 percent from a year earlier to 64.4 billion won ($48.2 million) in the January-September period, while operating profit reached 3 billion won and net profit totaled 2.5 billion won. R&D spending jumped to 20.7 billion won from 6.1 billion won a year earlier, an increase of roughly 3.4 times.

The results reflect Onconic’s strategy of reinvesting earnings from its first commercialized drug into the development of new treatments, particularly oncology therapies and drugs targeting metabolic disorders.

For the third quarter alone, however, revenue came to 17 billion won, affected by lower production during the summer holiday season. The company recorded an operating loss of 4.3 billion won as spending increased on new drug candidates and clinical trials in South Korea and overseas.

Its quarterly net loss widened to 7.7 billion won, partly reflecting a noncash foreign-exchange valuation loss on U.S. dollar-denominated assets received through an overseas licensing agreement.

Onconic expects its business to remain resilient in the fourth quarter as prescriptions of Jaqbo, South Korea’s 37th domestically developed new drug, continue to increase.

According to pharmaceutical market research firm UBIST, outpatient prescriptions of Jaqbo reached 28.75 billion won in the third quarter, up 109.6 percent from a year earlier.

Monthly prescription sales surpassed 10 billion won for the first time in October, reaching 10.27 billion won. That level would place the drug among the top 10 prescription medicines in South Korea by monthly prescription value, marking rapid growth roughly two years after its launch.

Onconic is also pursuing international commercialization.

Opening of the article, excerpted from Pulse (Maeil Business). To read the rest, open the article on the publisher's site.

Read the full article on Pulse (Maeil Business) Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (pulse.mk.co.kr)

Also worth reading